Abstract

Persistent bacteremia caused by Staphylococcus aureus (SA), especially methicillin-resistant SA (MRSA), is a significant cause of morbidity and mortality. Despite susceptibility phenotypes in vitro, persistent MRSA strains fail to clear with appropriate anti-MRSA therapy during bacteremia in vivo. Thus, identifying the factors that cause such MRSA persistence is of direct and urgent clinical relevance. To address the dynamics of MRSA persistence in the face of host immunity and typical antibiotic regimens, we developed a mathematical model based on the overarching assumption that phenotypic heterogeneity is a hallmark of MRSA persistence. First, we applied an ensemble modeling approach and obtained parameter sets that satisfied the condition of a minimum inoculum dose to establish infection. Second, by simulating with the selected parameter sets under vancomycin therapy which follows clinical practices, we distinguished the models resulting in resolving or persistent bacteremia, based on the total SA exceeding a detection limit after five days of treatment. Third, to find key determinants that discriminate resolving and persistent bacteremia, we applied a machine learning approach and found that the immune clearance rate of persister cells is a key feature. But, fourth, when relapsing bacteremia was considered, the growth rate of persister cells was also found to be a key feature. Finally, we explored pharmacological strategies for persistent and relapsing bacteremia and found that a persister killer, but not a persister formation inhibitor, could provide for an effective cure the persistent bacteremia. Thus, to develop better clinical solutions for MRSA persistence and relapse, our modeling results indicate that we need to better understand the pathogen-host interactions of persister MRSAs in vivo.

Highlights

  • Staphylococcus aureus (SA) is one of the most common life-threatening human pathogens [1,2,3]

  • To understand the dynamic interplay between the two bacterial populations when challenged by host immunity and vancomycin treatment, we developed a mathematical model and analyzed it in simulations of clinically relevant scenarios

  • Our work suggests that the immune clearance rate of persister Methicillin-resistant strains (MRSA) rather than the MRSA switch rate is a key determinant to establish persistent bacteremia

Read more

Summary

Introduction

Staphylococcus aureus (SA) is one of the most common life-threatening human pathogens [1,2,3]. MRSA bacteremia may be treated with anti-MRSA antibiotics, such as vancomycin or daptomycin. Such treatments fail in about 30–50% of patients, resulting in persistent bacteremia [4,5]. Persistent MRSA bacteremia, which is defined as 3–7 days positive blood culture post-therapy [1,6,7], is recognized as an urgent public health concern, as increased duration of bacteremia is associated with poor clinical outcomes, such as metastatic and complicated infections [6,8,9]. There are presently few therapeutic options for treating persistent MRSA bacteremia [1,10]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call